March 24 (Reuters) – India’s drug regulator tightened surveillance against unauthorized sale and promotion of weight-loss drugs, the country’s health ministry said on Tuesday, following local drugmakers launching a wave of generic, cheaper versions of Novo Nordisk’s blockbuster drugs Ozempic and Wegovy.
The regulator conducted inspections at 49 entities, including drug wholesalers, retailers, and slimming clinics, in recent weeks as it clamps down on the unauthorized sale and use of weight-loss drugs, according to the statement.
(Reporting by Rishika Sadam in Hyderabad and Urvi Dugar in Bengaluru; Editing by Rashmi Aich)
